Adverum Biotechnologies Net Worth
Adverum Biotechnologies Net Worth Breakdown | ADVM |
Adverum Biotechnologies Net Worth Analysis
Adverum Biotechnologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Adverum Biotechnologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Adverum Biotechnologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Adverum Biotechnologies' net worth analysis. One common approach is to calculate Adverum Biotechnologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Adverum Biotechnologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Adverum Biotechnologies' net worth. This approach calculates the present value of Adverum Biotechnologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Adverum Biotechnologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Adverum Biotechnologies' net worth. This involves comparing Adverum Biotechnologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Adverum Biotechnologies' net worth relative to its peers.
Enterprise Value |
|
To determine if Adverum Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adverum Biotechnologies' net worth research are outlined below:
| Adverum Biotechnologies had very high historical volatility over the last 90 days | |
| Adverum Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.6 M. Net Loss for the year was (117.17 M) with loss before overhead, payroll, taxes, and interest of (81.68 M). | |
| Adverum Biotechnologies currently holds about 235.84 M in cash with (90.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| Adverum Biotechnologies has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Mizuho cuts Adverum price target to 16, maintains outperform |
Adverum Biotechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adverum Biotechnologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adverum Biotechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Adverum Biotechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adverum Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adverum Biotechnologies backward and forwards among themselves. Adverum Biotechnologies' institutional investor refers to the entity that pools money to purchase Adverum Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 396.9 K | State Street Corp | 2024-06-30 | 278.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 258.5 K | Fmr Inc | 2024-09-30 | 234.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 206.7 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 204.6 K | Bank Of America Corp | 2024-06-30 | 176.1 K | Northern Trust Corp | 2024-09-30 | 155 K | Soleus Capital Management, L.p. | 2024-06-30 | 147.2 K | Bml Capital Management Llc | 2024-09-30 | 2.3 M | Tcg Crossover Management, Llc | 2024-09-30 | 2 M |
Follow Adverum Biotechnologies' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 134.18 M.Market Cap |
|
Project Adverum Biotechnologies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.84) | (0.79) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (1.40) | (1.33) |
When accessing Adverum Biotechnologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Adverum Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adverum Biotechnologies' profitability and make more informed investment decisions.
Evaluate Adverum Biotechnologies' management efficiency
Adverum Biotechnologies has return on total asset (ROA) of (0.2983) % which means that it has lost $0.2983 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7626) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies' management efficiency ratios could be used to measure how well Adverum Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.71. In addition to that, Return On Capital Employed is likely to grow to -0.79. At this time, Adverum Biotechnologies' Total Assets are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 1.3 M, while Other Current Assets are likely to drop about 4.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.28 | 11.14 | |
| Tangible Book Value Per Share | 8.28 | 11.11 | |
| Enterprise Value Over EBITDA | (0.67) | (0.71) | |
| Price Book Value Ratio | 0.91 | 0.96 | |
| Enterprise Value Multiple | (0.67) | (0.71) | |
| Price Fair Value | 0.91 | 0.96 | |
| Enterprise Value | 6.7 B | 6.4 B |
The leadership approach at Adverum Biotechnologies' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 54.1979 | Revenue 1000 K | Quarterly Revenue Growth (0.70) | Revenue Per Share 0.059 | Return On Equity (0.76) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adverum Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adverum Biotechnologies Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Adverum Biotechnologies Earnings per Share Projection vs Actual
Adverum Biotechnologies Corporate Management
| Jim Wang | Chief Officer | Profile | |
| Andrew Ramelmeier | Chief Officer | Profile | |
| Romuald Corbau | Chief Officer | Profile | |
| Kalliopi MD | Senior Development | Profile | |
| Michael Steel | Senior Quality | Profile | |
| Rabia MD | Chief Officer | Profile |
Already Invested in Adverum Biotechnologies?
The danger of trading Adverum Biotechnologies is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adverum Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adverum Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adverum Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.